Strategic goal 1 business objectives table

^[1]19 of the 72 Gavi-eligible countries had a National Immunisation Technical Advisory Group (NITAG) according to a 2008 WHO survey, of which only 2 had a NITAG meeting all 6 process indicators as defined by the World Health Organization (WHO): 1) Availability of formal written terms of reference; 2) Legislative or administrative basis establishing the committee; 3) Core membership with at least 5 main expertise areas represented among members; 4) Committee meets at least once a year; 5) Agenda and expectations from the committee together with background materials distributed at least a week ahead of meetings; 6) Declaration of interests by committee members. NITAGs review all available scientific and programmatic data to arrive at policy decisions, also taking into consideration local surveillance data.

^[2] All Gavi supported countries should have a National Regulatory Authority (NRA) able to perform registration of vaccines, assess vaccine performance through post-marketing surveillance, and assess and inspect clinical trials conducted in their country. There are 10 producing countries where functional NRAs are essential to meet future global demand and develop or sustain pre-qualified products. Support will be concentrated on a first group of these countries with high potential to increase supply and will be extended to other countries about to introduce NUV and where clinical trials have been conducted (mostly in Africa, some in Asia, Central Europe, and South America).

^[3]Coverage data are used to prioritise country support and to concentrate efforts to strengthen immunisation systems. 40% of Gavi-supported countries currently have more than a 5 percentage point difference between DTP3 coverage estimates and WHO/UNICEF estimates.

^[4]Includes communication plan, fact sheets, media advisory, press release, advocate plans, etc. Assumes five communication packets developed per annum based on previous trends.

^[5] Does not include Comprehensive Multi-year Plans for Immunisation (cMYPs). Work on cMYPs is included in Strategic goal 3.

^[6] Source: Country Annual Progress Reports (APRs)

^[7]Assessment of successful introduction is based on a checklist including the following: Independent Review Committee-endorsed introduction plan, appropriate training of health care workers, adaptation of Expanded Programme of Immunization (EPI) materials and guidelines, cold chain inventory, Effective Vaccine Management (EVM) assessment, community mobilisation, and coverage monitoring.

^[8]Surveillance data quality indicators as defined by WHO (http://www.who.int/nuvi/Summary%20Report.pdf). Surveillance systems are used for generation of local data for decision-making, provision of impact data to sustain domestic and external financing subsequent to Gavi support, monitoring of changes in disease epidemiology (e.g. genotype and serotype shifts), provision of data for burden of disease and cost-effectiveness analyses, outbreak detection and response, monitoring of and appropriate response to adverse events.